Organogenesis (NASDAQ:ORGO) Stock Price Down 6.1% – What’s Next?

Organogenesis (NASDAQ:ORGO) shares traded down 6.1% during trading on Tuesday . The company traded as low as $5.48 and last traded at $5.6250. 982,246 shares changed hands during trading, a decline of 31% from the average session volume of 1,433,160 shares. The stock had previously closed at $5.99.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on ORGO shares. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research report on Wednesday. BTIG Research increased their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald upped their price target on shares of Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Organogenesis Stock Performance

The company has a market capitalization of $649.78 million, a PE ratio of -42.67 and a beta of 1.68. The stock’s fifty day simple moving average is $4.61 and its 200-day simple moving average is $4.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Organogenesis will post -0.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Cerity Partners LLC boosted its holdings in shares of Organogenesis by 48.2% during the first quarter. Cerity Partners LLC now owns 74,880 shares of the company’s stock worth $323,000 after purchasing an additional 24,362 shares during the last quarter. CWM LLC lifted its position in Organogenesis by 8.9% during the first quarter. CWM LLC now owns 63,894 shares of the company’s stock worth $276,000 after buying an additional 5,239 shares during the period. Victory Capital Management Inc. purchased a new position in Organogenesis during the first quarter worth about $67,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Organogenesis in the 1st quarter worth about $631,000. Finally, Mackenzie Financial Corp grew its holdings in Organogenesis by 65.4% in the 1st quarter. Mackenzie Financial Corp now owns 126,303 shares of the company’s stock valued at $546,000 after buying an additional 49,950 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.